{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:53Z","timestamp":1782337253144,"version":"3.54.5"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.critrevonc.2026.105384","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:39:53Z","timestamp":1779583193000},"page":"105384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Exploiting CD36 as a self-facilitated endocytic receptor for PROTAC-mediated protein degradation: A new paradigm in cancer therapy"],"prefix":"10.1016","volume":"224","author":[{"given":"Jiayan","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkai","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4661-8864","authenticated-orcid":false,"given":"Guihai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12885-023-10836-z","article-title":"Tumor-infiltrating CD36+ CD8+ T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer","volume":"23","author":"Ao","year":"2023","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105384_bib2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4049\/jimmunol.1100350","article-title":"Class B scavenger receptor types I and II and CD36 mediate bacterial recognition and proinflammatory signaling induced by Escherichia coli, lipopolysaccharide, and cytosolic chaperonin 60","volume":"188","author":"Baranova","year":"2012","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105384_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105384_bib4","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.2174\/0115680266309968240621072550","article-title":"PROTAC beyond cancer-exploring the new therapeutic potential of proteolysis targeting chimeras","volume":"24","author":"Bhole","year":"2024","journal-title":"Curr. Top. Med. Chem."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105384_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/gbe\/evad218","article-title":"Phylogenetic and protein structure analyses provide insight into the evolution and diversification of the CD36 domain \u201cApex\u201d among scavenger receptor class B proteins across Eukarya","volume":"15","author":"Boohar","year":"2023","journal-title":"Genome Biol. Evol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105384_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1676414","article-title":"PROTAC: a revolutionary technology propelling small molecule drugs into the next golden age","volume":"15","author":"Cai","year":"2025","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13046-025-03276-z","article-title":"CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer","volume":"44","author":"Castagnoli","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105384_bib9","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","article-title":"Recent advances in pro-PROTAC development to address on-target off-tumor toxicity","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105384_bib10","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1158\/1535-7163.MCT-24-1091","article-title":"PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105384_bib11","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211314","article-title":"CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate","volume":"219","author":"Chen","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105384_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122038","article-title":"situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy","volume":"295","author":"Cho","year":"2023","journal-title":"Biomaterials"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105384_bib13","doi-asserted-by":"crossref","first-page":"11214","DOI":"10.3390\/ijms252011214","article-title":"Proteolysis targeting chimera agents (PROTACs): new hope for overcoming the resistance mechanisms in Oncogene-Addicted Non-Small cell lung cancer","volume":"25","author":"Cordani","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105384_bib14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/imm.13887","article-title":"FOXP3 Transcriptionally Activates Fatty Acid Scavenger Receptor CD36 in Tumour-Induced Treg Cells","volume":"174","author":"Dhar","year":"2025","journal-title":"Immunology"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105384_bib15","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1039\/D2CS00387B","article-title":"Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders","volume":"51","author":"Diehl","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105384_bib16","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.cell.2020.10.038","article-title":"Mapping the degradable kinome provides a resource for expedited degrader development","volume":"183","author":"Donovan","year":"2020","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105384_bib17","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019 chemical space: recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105384_bib18","doi-asserted-by":"crossref","first-page":"10005","DOI":"10.1021\/acs.jmedchem.8b01732","article-title":"Why some targets benefit from beyond rule of five drugs","volume":"62","author":"Egbert","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105384_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.133680","article-title":"Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment","volume":"275","author":"Fan","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105384_bib20","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/cells12121605","article-title":"The role of CD36 in cancer progression and its value as a therapeutic target","volume":"12","author":"Feng","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40364-024-00638-1","article-title":"Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics","volume":"12","author":"Feng","year":"2024","journal-title":"Biomark. Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105384_bib22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib23","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1038\/s41467-024-50735-w","article-title":"A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy","volume":"15","author":"Gao","year":"2024","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105384_bib24","first-page":"1934","article-title":"Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice","volume":"118","author":"Ghosh","year":"2008","journal-title":"J. Clin. Invest"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105384_bib25","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.critrevonc.2026.105384_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1079076","article-title":"Role of CD36 in cancer progression, stemness, and targeting","volume":"10","author":"Guerrero-Rodriguez","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105384_bib27","article-title":"A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML","volume":"5","author":"Guo","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib28","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1038\/s41467-020-18565-8","article-title":"CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis","volume":"11","author":"Hao","year":"2020","journal-title":"Nat. Commun."},{"issue":"43","key":"10.1016\/j.critrevonc.2026.105384_bib29","doi-asserted-by":"crossref","first-page":"23487","DOI":"10.1002\/ange.202107347","article-title":"Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer","volume":"133","author":"He","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105384_bib30","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41589-021-00878-4","article-title":"Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity","volume":"17","author":"Imaide","year":"2021","journal-title":"Nat. Chem. Biol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105384_bib31","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1194\/jlr.RA120000648","article-title":"SSO and other putative inhibitors of FA transport across membranes by CD36 disrupt intracellular metabolism, but do not affect FA translocation","volume":"61","author":"Jay","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.critrevonc.2026.105384_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.imlet.2023.12.002","article-title":"CD36 as a double-edged sword in cancer","volume":"265","author":"Jiang","year":"2024","journal-title":"Immunol. Lett."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105384_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400267","article-title":"Proteolysis targeting chimeras (PROTACs) in breast cancer therapy","volume":"19","author":"Jin","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.critrevonc.2026.105384_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2024.1434002","article-title":"Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed","volume":"15","author":"Kanbar","year":"2024","journal-title":"Front. Genet"},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105384_bib35","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","article-title":"PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics","volume":"39","author":"Khan","year":"2020","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105384_bib36","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105384_bib37","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1021\/acsmedchemlett.0c00265","article-title":"Understanding and improving the membrane permeability of VH032-based PROTACs","volume":"11","author":"Klein","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105384_bib38","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1245\/s10434-019-07927-2","article-title":"Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma","volume":"27","author":"Kubo","year":"2020","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105384_bib39","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/biom12050706","article-title":"Key molecules of fatty acid metabolism in gastric cancer","volume":"12","author":"Li","year":"2022","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105384_bib40","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2174\/0118715206353634241111113338","article-title":"CD36 as a therapeutic target in tumor microenvironment and lipid metabolism","volume":"25","author":"Li","year":"2025","journal-title":"Anticancer Agents Med. Chem."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105384_bib41","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13046-025-03332-8","article-title":"Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatment","volume":"44","author":"Li","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105384_bib43","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.3390\/molecules27248828","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy: present and future","volume":"27","author":"Li","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib44","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105384_bib45","doi-asserted-by":"crossref","first-page":"8133","DOI":"10.3390\/curroncol29110642","article-title":"CD36 and its role in regulating the tumor microenvironment","volume":"29","author":"Liao","year":"2022","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/bloodadvances.2022008121","article-title":"Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models","volume":"7","author":"Lim","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105384_bib47","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.semcancer.2022.07.001","article-title":"Targeting micro-environmental pathways by PROTACs as a therapeutic strategy","volume":"86","author":"Liu","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105384_bib48","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41419-023-06078-3","article-title":"The activated CD36-Src axis promotes lung adenocarcinoma cell proliferation and actin remodeling-involved metastasis in high-fat environment","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105384_bib49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.actbio.2025.02.012","article-title":"Proteolysis-targeting chimera-doxorubicin conjugate nanoassemblies for dual treatment of EGFR-TKI sensitive and resistant non-small cell lung cancer","volume":"195","author":"Ma","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.critrevonc.2026.105384_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107984","article-title":"Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies","volume":"154","author":"Malarvannan","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib51","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1186\/s12885-021-08482-4","article-title":"CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix","volume":"21","author":"Martini","year":"2021","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105384_bib52","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3390\/ijms20061348","article-title":"Fatty acid synthesis and degradation interplay to regulate the oxidative stress in cancer cells","volume":"20","author":"Mikalayeva","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105384_bib53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib54","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13046-019-1387-5","article-title":"Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer","volume":"38","author":"Noblejas-L\u00f3pez","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib55","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13046-020-01672-1","article-title":"Proteolysis targeting chimeras (PROTACs) in cancer therapy","volume":"39","author":"Oca\u00f1a","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7635","key":"10.1016\/j.critrevonc.2026.105384_bib56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nature20791","article-title":"Targeting metastasis-initiating cells through the fatty acid receptor CD36","volume":"541","author":"Pascual","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-nutr-071812-161220","article-title":"Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism","volume":"34","author":"Pepino","year":"2014","journal-title":"Annu. Rev. Nutr."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib58","doi-asserted-by":"crossref","DOI":"10.4251\/wjgo.v17.i1.98409","article-title":"Dysregulation of genes involved in the long-chain fatty acid transport in pancreatic ductal adenocarcinoma","volume":"17","author":"Poenaru","year":"2025","journal-title":"World J. Gastrointest. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105384_bib59","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acschembio.9b00092","article-title":"SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate","volume":"14","author":"Roy","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.critrevonc.2026.105384_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177367","article-title":"Obacunone potentiated PD-1 immunotherapy in pancreatic cancer by mediating CD36","volume":"994","author":"Sang","year":"2025","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105384_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.157044","article-title":"Matrine targets \u03b2-catenin and blocks the formation of \u03b2-catenin\/TCF7L2 complex to promote ferroptosis and inhibit metastasis in triple-negative breast cancer","volume":"145","author":"Sang","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.critrevonc.2026.105384_bib62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.abb.2014.01.025","article-title":"Protein mediated fatty acid uptake: synergy between CD36\/FAT-facilitated transport and acyl-CoA synthetase-driven metabolism","volume":"546","author":"Schneider","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105384_bib63","doi-asserted-by":"crossref","first-page":"6057","DOI":"10.4049\/jimmunol.168.12.6057","article-title":"CD36 or \u03b1v\u03b23 and \u03b1v\u03b25 integrins are not essential for MHC class I cross-presentation of cell-associated antigen by CD8\u03b1+ murine dendritic cells","volume":"168","author":"Schulz","year":"2002","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105384_bib64","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1021\/acsmedchemlett.0c00194","article-title":"Systematic investigation of the permeability of androgen receptor PROTACs","volume":"11","author":"Scott","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105384_bib65","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1021\/acs.jmedchem.8b00686","article-title":"Two decades under the influence of the rule of five and the changing properties of approved oral drugs: miniperspective","volume":"62","author":"Shultz","year":"2018","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105384_bib66","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","article-title":"Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies","volume":"38","author":"Si","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105384_bib67","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.2147\/IJN.S448684","article-title":"Nano-proteolysis targeting chimeras (Nano-PROTACs) in cancer therapy","volume":"19","author":"Song","year":"2024","journal-title":"Int. J. Nanomed."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105384_bib68","article-title":"Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response","volume":"4","author":"Tang","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105384_bib69","doi-asserted-by":"crossref","first-page":"12502","DOI":"10.1039\/D4NR01006J","article-title":"Design and synthesis of nucleic acid nano-environment interactome-targeting small molecule PROTACs and their anticancer activity","volume":"16","author":"Tanga","year":"2024","journal-title":"Nanoscale"},{"issue":"40","key":"10.1016\/j.critrevonc.2026.105384_bib70","doi-asserted-by":"crossref","first-page":"27382","DOI":"10.1021\/jacs.4c06402","article-title":"ClickRNA-PROTAC for tumor-selective protein degradation and targeted cancer therapy","volume":"146","author":"Teng","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.critrevonc.2026.105384_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116221","article-title":"vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs)","volume":"41","author":"Tomoshige","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105384_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.126413","article-title":"Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations","volume":"252","author":"Vartak","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.critrevonc.2026.105384_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108725","article-title":"Powering up targeted protein degradation through active and passive tumour-targeting strategies: current and future scopes","volume":"263","author":"Venkatesan","year":"2024","journal-title":"Pharmacol. Ther."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105384_bib74","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.7150\/thno.36037","article-title":"CD36 tango in cancer: signaling pathways and functions","volume":"9","author":"Wang","year":"2019","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib75","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41698-024-00774-9","article-title":"Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105384_bib76","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105384_bib77","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.cell.2025.03.036","article-title":"CD36-mediated endocytosis of proteolysis-targeting chimeras","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105384_bib78","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3390\/pharmaceutics17081037","article-title":"Recent advances in nanomedicine: cutting-edge research on nano-PROTAC delivery systems for cancer therapy","volume":"17","author":"Wu","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105384_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115834","article-title":"Ligand-dependent CD36 functions in cancer progression, metastasis, immune response, and drug resistance","volume":"168","author":"Xia","year":"2023","journal-title":"Biomed. Pharm."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105384_bib80","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","article-title":"Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors","volume":"54","author":"Xu","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105384_bib81","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.freeradbiomed.2019.02.021","article-title":"CD36 signaling in vascular redox stress","volume":"136","author":"Yang","year":"2019","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib82","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1038\/s41467-022-33349-y","article-title":"CD36-mediated metabolic crosstalk between tumor cells and macrophages affects liver metastasis","volume":"13","author":"Yang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105384_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155905","article-title":"Interplay of CD36, autophagy, and lipid metabolism: insights into cancer progression","volume":"155","author":"Yang","year":"2024","journal-title":"Metabolism"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105384_bib84","doi-asserted-by":"crossref","first-page":"18208","DOI":"10.1021\/jacs.5c04857","article-title":"Reactive oxygen species-instructed supramolecular assemblies enable bioorthogonally activatable protein degradation for pancreatic cancer","volume":"147","author":"Yao","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105384_bib85","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202411454","article-title":"An oral PROTAC targeting HPK1 degradation potentiates anti-solid tumor immunity","volume":"37","author":"Yao","year":"2025","journal-title":"Adv. Mater."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105384_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202314132","article-title":"PROTAC prodrug-integrated nanosensitizer for potentiating radiation therapy of cancer","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105384_bib87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105384_bib88","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/s41401-024-01266-z","article-title":"Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy","volume":"45","author":"Zou","year":"2024","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:54:58Z","timestamp":1781193298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":88,"alternative-id":["S1040842826002714"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105384","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting CD36 as a self-facilitated endocytic receptor for PROTAC-mediated protein degradation: A new paradigm in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105384"}}